<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5105">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262051</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02232</org_study_id>
    <nct_id>NCT03262051</nct_id>
  </id_info>
  <brief_title>Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot</brief_title>
  <official_title>Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytochromes P450, main enzymes of drug metabolism, play a prominent role in the first-pass&#xD;
      metabolism of oral substances. Inter-individual variability in their activity due to genetic&#xD;
      and environmental factors has been observed and may be associated with adverse therapeutic&#xD;
      outcomes (ineffectiveness or toxicity). The inflammation, whether acute or chronic, can&#xD;
      theoretically modulate the pharmacokinetics of drugs by modulating enzyme activity. Indeed,&#xD;
      in vitro data and animal models, as well as more limited data in humans, indicate a&#xD;
      down-regulation of CYP in the context of inflammation.&#xD;
&#xD;
      The cocktail approach developed and validated in Geneva (&quot;cocktail Geneva&quot;) measures the&#xD;
      activity of several CYP simultaneously using micro-doses of probe drugs and facilitating&#xD;
      sampling (10uL capillary blood) on a dried blood spot.&#xD;
&#xD;
      We intend to measure the activity of CYP in an acute inflammation model (hip surgery and&#xD;
      SARS-CoV-2 infection) and chronic inflammation (rheumatoid arthritis, RA). The effect of the&#xD;
      biological agent tocilizumab (anti IL-6 receptor) in a treated patient subgroup (patients&#xD;
      treated regardless of our study) will be measured after 3 months of treatment.&#xD;
&#xD;
      The main objective is to determine if interleukin 6 levels are correlated with the activity&#xD;
      of CYP450 in patients with acute (orthopedic surgery - hip or SARS-CoV-2 infection) or&#xD;
      chronic inflammation (RA).&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To correlate CYPs activities with the levels of other inflammatory markers (CRP, TNF-α,&#xD;
           IL-1β, IFN-γ);&#xD;
&#xD;
        -  To assess correlation between markers of inflammation, CYP activities and the intensity&#xD;
           of fatigue and pain;&#xD;
&#xD;
        -  To assess if tocilizumab reverse CYP activity in patients with RA after 3 months&#xD;
           treatment;&#xD;
&#xD;
        -  To assess if SARS-CoV-2 infection modify pharmacokinetic parameters of concomitant&#xD;
           medications which are CYPs substrates&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the impact of IL6 levels on the activity of CYPs in patients with acute (post orthopaedic surgery -hip or post SARS-CoV-2 infection) and chronic (rheumatoid arthritis) inflammation.</measure>
    <time_frame>1 week</time_frame>
    <description>The phenotyping probe drugs used in this study will be given as 2 capsules: one capsule of Omeprazole 10 mg and one capsule containing the remaining probe 'cocktail' drugs (caffeine 50 mg, flurbiprofen 10 mg, dextromethorphan 10 mg, midazolam 1 mg, bupropion 20 mg).&#xD;
The enzymatic activities of the following CYP will be assessed by specific metabolite/probe single point concentration ratios (metabolic ratios-MR) in capillary blood:&#xD;
CYP1A2&#xD;
CYP2B6&#xD;
CYP2C9&#xD;
CYP2C19&#xD;
CYP2D6&#xD;
CYP3A4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between the activity of CYPs and CRP levels</measure>
    <time_frame>1 week or 3 months</time_frame>
    <description>The routine concentration of the inflammatory marker C-reactive protein (CRP) will be measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between the activity of CYPs and TNF-α levels</measure>
    <time_frame>1 week or 3 months</time_frame>
    <description>TNF-α blood concentrations will be measured by using the Fluorokine MAP Cytokine Multiplex Elisa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between the activity of CYPs and IL-1β levels</measure>
    <time_frame>1 week</time_frame>
    <description>IL-1β blood concentrations will be measured by using the Fluorokine MAP Cytokine Multiplex Elisa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between the activity of CYPs and IFN-γ levels</measure>
    <time_frame>1 week</time_frame>
    <description>IFN-γ blood concentrations will be measured by using the Fluorokine MAP Cytokine Multiplex Elisa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess if tocilizumab reverse the activity of CYP in patients with RA after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of CYP function before and 3 months after the beginning of the Tocilizumab treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess if SARS-CoV-2 infection modify pharmacokinetic parameters of concomitant medications which are CYPs substrates</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of plasma concentrations of CYPs substrates, when COVID-19 patients received any CYPs substrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between inflammatory markers, CYP function and intensity of fatigue (MFI) and pain (NRS)</measure>
    <time_frame>1 week</time_frame>
    <description>Function and intensity of fatigue will be measured with the validated French version of the Multidimensional Fatigue Inventory; pain will be measured with the numeric rating scale (NRS) 0 to 10 (0 = no pain and 10 = worst pain imaginable).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Patient with acute inflammation (surgery)</arm_group_label>
    <description>patients undergoing hip surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with chronic inflammation</arm_group_label>
    <description>patients with rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with acute inflammation (SARS-CoV-2 infection)</arm_group_label>
    <description>patients with SARS-CoV-2 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CYP phenotyping</intervention_name>
    <description>Phenotyping using a simplified version of the Geneva cocktail</description>
    <arm_group_label>Patient with acute inflammation (SARS-CoV-2 infection)</arm_group_label>
    <arm_group_label>Patient with acute inflammation (surgery)</arm_group_label>
    <arm_group_label>Patient with chronic inflammation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients included in the study will be patients with either chronic inflammation (patients&#xD;
        with rheumatoid arthritis) or with acute inflammation (patients undergoing hip surgery or&#xD;
        with COVID-19). All patients will be recruited at the Geneva University Hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        --&gt; Inclusion Criteria: For hip surgery and chronic inflammation groups&#xD;
&#xD;
          -  Male and female patients diagnosed with rheumatoid arthritis or undergoing an elective&#xD;
             hip surgery&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Understanding of French language and ability to give a written inform consent&#xD;
&#xD;
        For SARS-CoV-2 infection group&#xD;
&#xD;
          -  Male and female patients diagnosed with SARS-CoV-2 infection (positive RT-PCR) and CRP&#xD;
             &gt; 30 mg/L&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Understanding of French language and ability to give a written inform consent&#xD;
&#xD;
             --&gt; Exclusion Criteria: For hip surgery and chronic inflammation groups&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Severe cardiac failure, severe edema or ascites&#xD;
&#xD;
          -  Severe COPD or pulmonary embolism requiring oxygen&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Renal impairment (defined as serum creatinine concentrations &gt; 1.5 x ULN)&#xD;
&#xD;
          -  Hepatic impairment (alteration of hepatic tests AST, ALT, bilirubin, GGT &gt;2 x ULN)&#xD;
&#xD;
          -  Inability to give blood samples&#xD;
&#xD;
          -  Sensitivity to any of the drugs used&#xD;
&#xD;
          -  Intake of drugs altering CYPs activity (based on [1]) except for tocilizumab&#xD;
&#xD;
        For SARS-CoV-2 infection group&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Hospitalized in intensive care unit at time of inclusion&#xD;
&#xD;
          -  Hospitalized in intermediate care unit at time of inclusion&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Renal impairment (glomerular filtration rate &lt; 30 mL/min/1.73m2)&#xD;
&#xD;
          -  Hepatic impairment (Child-Pugh score B and C)&#xD;
&#xD;
          -  Inability to give blood samples&#xD;
&#xD;
          -  Sensitivity to any of the drugs used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caroline Samer, MD</last_name>
    <phone>+41 22 382 99 47</phone>
    <email>caroline.samer@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geneva University Hospitals, HUG</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Samer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Caroline Samer</investigator_full_name>
    <investigator_title>Doctor, University Hospital, Geneva</investigator_title>
  </responsible_party>
  <keyword>cytochromes P450</keyword>
  <keyword>chronic inflammation</keyword>
  <keyword>genotyping</keyword>
  <keyword>phenotyping</keyword>
  <keyword>acute inflammation</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>surgery</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

